KUALA LUMPUR: The Health Ministry has assured the management of medications, including for diabetes treatment, remains robust despite recent disruptions in the supply chain of human insulin at public healthcare facilities.
"The recent disruption in the supply of human insulin at MoH facilities was due to production issues at a local supplier's facility and we have taken several measures to ensure that patients continue to receive uninterrupted treatment," it said in a statement, today.
The ministry has increased the use of insulin analogues and oral hypoglycaemic agents based on clinical assessments by treating doctors.
It said that out of the 41 medications used in the formulary for diabetes treatment, only human insulin faced supply issues, ensuring that overall diabetes management for MoH patients remains unaffected.
On Aug 12, the ministry announced enhancements to its procurement policy to ensure the security, availability, and optimal value for pharmaceutical products and medical devices.
"Efforts to diversify insulin supply sources are being intensified, with local manufacturers and international suppliers encouraged to register their insulin products with the National Pharmaceutical Regulatory Agency (NPRA) for priority evaluation," said MoH.
The ministry emphasised its commitment to safeguarding public health and will not compromise on issues affecting the supply of essential medications, a crucial aspect of healthcare.
It also advised diabetic patients to consult their doctors for ongoing guidance and to seek accurate information from reliable sources regarding health issues.
The 2023 National Health and Morbidity Survey revealed that one in six (15.6 per cent) adults in Malaysia has diabetes, while 84 per cent of those aged 18-29 are unaware of their condition.
The ministry urges the public to take proactive steps in self-health management, in line with the National Healthy Malaysia Agenda, by adopting a balanced diet, staying active with a healthy lifestyle, and undergoing regular health screenings to manage any disease risks, especially non-communicable diseases.